Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunity Against COVID-19 and Safety Following Evusheld in Immunocompromised Children and Adolescents
TCTR20230406002Phase 4Completed
- Sponsor
- Faculty of Medicine Siriraj Hospital, Mahidol University
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of tixagevimab + cilgavimab in coronavirus disease 2019 (COVID-19), sponsored by Faculty of Medicine Siriraj Hospital, Mahidol University. Started Feb 2023; status: completed.
02
Drugs
tixagevimab + cilgavimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20230406002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20230406002.